Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
Mason
John O
JO
Retina Consultants of Alabama, Callahan Eye Foundation Hospital, and the University of Alabama at Birmingham School of Medicine, Department of Ophthalmology, Birmingham, Alabama 35233, USA.
Albert
Michael A
MA
Mays
Andrew
A
Vail
Rachel
R
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000869:Anterior Eye Segment / Q000098:blood supply; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab